filgrastim
Selected indexed studies
- Filgrastim biosimilar (EP2006): A review of 15 years' post-approval evidence. (Crit Rev Oncol Hematol, 2024) [PMID:38401695]
- The evolution of value with filgrastim in oncology. (Future Oncol, 2019) [PMID:30835142]
- Filgrastim induced thrombocytopenia. (BMJ Case Rep, 2020) [PMID:32606115]
_Worker-drafted node — pending editorial review._
Connections
No connections recorded yet.
Sources
- Filgrastim biosimilar (EP2006): A review of 15 years' post-approval evidence. (2024) pubmed
- The evolution of value with filgrastim in oncology. (2019) pubmed
- Filgrastim induced thrombocytopenia. (2020) pubmed
- Filgrastim, fibrinolysis, and neovascularization. (2022) pubmed
- Zarxio--a filgrastim biosimilar. (2016) pubmed
- Filgrastim for the treatment of hematopoietic acute radiation syndrome. (2015) pubmed
- Filgrastim associations with CAR T-cell therapy. (2021) pubmed
- Tbo-Filgrastim: A Review in Neutropenic Conditions. (2016) pubmed
- Filgrastim (r-metHuG-CSF) in the 21st century: SD/01. (2001) pubmed
- Filgrastim. A review of its pharmacological properties and therapeutic efficacy in neutropenia. (1994) pubmed